Shots:

• Following the IND approval- Celularity will initiate P-I/II study assessing CYNK-001 in 86 patients with COVID-19. The company deems CYNK-001 is the first FDA’s IND cleared immunotherapy to treat COVID-19 infected adults
• Cell therapy works by boosting the body’s early immune response in a way it could target the coronavirus. CYNK-001 limits the SARS-CoV-2 replication and disease progression by eliminating the infected cells
• CYNK-001 is the only cryopreserved allogeneic- off-the-shelf NK cell therapy- being developed from placental hematopoietic stem cells and being investigated for hematologic cancers and solid tumors

Click here to­ read full press release/ article | Ref: Celularity | Image: Celularity